Medicare Plans Releases Survey Results Regarding Medical Cannabis Coverage
Medicare Plans, a patient support center that provides resources for better understanding Medicare, recently conducted a survey about the idea of Medicare coverage for medical cannabis treatment and products. Here are some highlights from their results.
Recently, Medicare Plans, a patient support center that helps provide resources for understanding Medicare, conducted a survey of current Medicare recipients on their opinions of Medicare coverage for medical cannabis treatment and products (1). The survey was conducted online with 1250 Americans ages 65 and over surveyed. It covered topics such as past and current cannabis use, political affiliations, and how much patients spent on cannabis products per month. Medicare Plans released their survey results this month.
Some of the most prominent findings, according to Medicare Plans, included:
- 1 in 5 Medicare recipients currently use medical cannabis
- 23% have used medical cannabis in the past
- 66% of Medicare recipients “strongly agree” or “agree” that Medicare should cover medical cannabis
- 59% of those who support Medicare coverage for medical cannabis say it's because it can be effective where other treatments fail
- 38% of Medicare recipients who use medical cannabis do not want Medicare coverage because they fear it will increase the price
Medicare Plans pointed out that currently the use of medical cannabis is legal in 37 states, four territories, and the District of Columbia. However, because cannabis is both illegal at the federal level and, in most cases, not approved by the US Food and Drug Administration (FDA), health insurance does not pay for it. Medicare Plans also noted that with the recent passing of the Marijuana Opportunity Reinvestment and Expungement (MORE) Act in the House of Representatives, the question of whether insurance should cover medical cannabis may soon need to be addressed.
To see the survey results in detail, please visit: https://www.medicareplans.com/1-in-5-medicare-recipients-use-medical-marijuana/
References
Work Smarter, Not Harder: How ASTM Standards for Cannabinoids Improve Your Operations
December 3rd 2024ASTM Standards D8557-24 and D8556-24, provide unified guidelines for GMP (Good Manufacturing Practices) and QMS (Quality Management Systems) in cannabis operations. These standards enhance compliance, product safety, and operational consistency across the industry for the benefit of operators, consumers, and other stakeholders in the industry.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
